

CURIS INC

Form 4

September 09, 2016

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Aurigene Discovery Technologies
Ltd

(Last) (First) (Middle)

39-40, KIADB INDUSTRIAL
AREA,, PHASE II, ELECTRONIC
CITY HOSUR ROAD

(Street)

BANGALORE,
KARNATAKA, K7 560100

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
CURIS INC [CRIS]

3. Date of Earliest Transaction
(Month/Day/Year)
01/18/2015

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____X____ 10% Owner
____ Officer (give title below) ____ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
____ Form filed by One Reporting Person
X Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value \$0.01 per share	09/07/2016	09/07/2016	P		10,208,333	A	\$ 2.4
					27,328,464	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form
displays a currently valid OMB control
number.**

SEC 1474
(9-02)

Edgar Filing: CURIS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Aurigene Discovery Technologies Ltd 39-40, KIADB INDUSTRIAL AREA, PHASE II, ELECTRONIC CITY HOSUR ROAD BANGALORE, KARNATAKA, K7 560100			X	
DR REDDYS LABORATORIES LTD 8-2-337, ROAD NO. 3, BANJARA HILLS HYDERABAD, TELANGANA, K7 500 034			X	
Dr. Reddy's Holdings Ltd 7-1-27, AMEERPET HYDERABAD, TELANGANA, K7 500 016			X	

Signatures

AURIGENE DISCOVERY TECHNOLOGIES LIMITED, By: /s/ Ashish Lath, Name: Ashish Lath, Title: Director of Finance	09/08/2016
__Signature of Reporting Person	Date
DR. REDDY'S LABORATORIES LIMITED, By: /s/ Saumen Chakraborty, Name: Saumen Chakraborty, Title: President and Chief Financial Officer	09/08/2016
__Signature of Reporting Person	Date
DR. REDDY'S HOLDINGS LIMITED, By:/s/ G V Prasad, Name: G V Prasad, Title: Director	09/08/2016
__Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Aurigene Discovery Technologies Limited ("Aurigene") has acquired from the Issuer an additional 10,208,333 shares of Common

1. This Form 4 is being filed jointly by (i) Aurigene Discovery Technologies Limited ("Aurigene"), which (after giving effect to the transactions described in Item 1 of Part I of this Form 4) will be a subsidiary of Aurigene Limited ("Aurigeneltd"), a company incorporated in India, and (ii) Aurigeneltd, which (after giving effect to the transactions described in Item 1 of Part I of this Form 4) will be a subsidiary of Aurigene.
2. In the event that DRHL could be deemed to "beneficially own" the Reported Securities as the result of its ownership of voting securities of Aurigeneltd, the Reported Securities will be deemed to be owned by Aurigeneltd.
3. The filing of this Form 4 shall not be deemed an admission for the purposes of Section 16 or any other purpose that any reported insider has or has not acquired the Reported Securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.